medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 2

<< Back Next >>

Rev Mex Neuroci 2008; 9 (2)

Clinical features and management of the pathology associated to cocaine consume

Souza y MM, Cruz ML

Language: Spanish
References: 57
Page: 141-149
PDF size: 73.54 Kb.


ABSTRACT

An international and national abuse/dependence on cocaine numeric view is presented, which offers a quick and complete overview of the topic, in terms of consumer demand, omitting individual, family and group repercussions derived from its sociolegal aspects. The educational purpose of this statement, in terms spread out the characteristics of this disease and its clinical variations will make it easy to be recognized and properly evaluated by health personnel. Accordingly, the main pharmacologic and chemical characteristics of the substance are described, its origin and variety of products that come out for consumption. To the clinical aspects of the article (intoxication and withdrawal syndromes, and the induced: delusional syndrome, psychotic disorder with hallucinations or delusional thoughts, and mood, anxiety, sexual and sleep disorders) the international recommendations for diagnosis and treatment are added, according to the conditions and national resources. It is emphasized the importance of continuing with joint handling (pharmacological and psychotherapeutic) once the acute symptomatology are controlled, through intervention on interpersonal conflicts, changes in the paper, labor problems and other interpersonal deficits, as it has been documented a higher efficiency than the symptomatic handling. Lastly, attention is focused on the prevention of relapse, to encourage complete remission of the symptoms, and ensure an effective case handling in the long term.


REFERENCES

  1. Oficina de las Naciones Unidas Contra la Droga y el Delito, ONUDD, Reporte Mundial 2004, Ginebra; 2004.

  2. Oficina de las Naciones Unidas Contra la Droga y el Delito (ONUDD), World Drug Report 2007, Organización de las Naciones Unidas, Ginebra; 2007.

  3. Chasin L, Presson CC, Rose J, Sherman S. What is addiction? Aged related differences in the meaning of addiction. Drug and Alcohol Dependence 2007; 87: 30-8.

  4. Secretaría de Salud (SSA). Encuesta Nacional de Adicciones, ENA, 2002, Consejo Nacional Contra las Adicciones, Dirección General de Epidemiología, Instituto Nacional de Psiquiatría “Ramón de la Fuente Muñiz”. México: Instituto Nacional de Estadística, Geografía e Informática; 2003.

  5. INP-SEP. Consumo de drogas, alcohol y tabaco en estudiantes del DF, medición otoño 2003. Reporte global. México: INP-SEP; 2003.

  6. Castillo FPI, Gutiérrez LAD. Consumo de drogas en pacientes de ingreso a tratamiento en Centros de Integración Juvenil julio-diciembre 2005/2006. CIJ. Dirección de Investigación y Enseñanza, Subdirección de Investigación. Informes de Investigación 06/05 a 07/01. Centros de Integración Juvenil, A.C.; 2008.

  7. Carroll E. Coca: The Plant and its use. In: Cocaine 1977. NIDA Research Monograph Series 1977; 13: 35-45.

  8. Hollander J. The management of cocaine-associated myocardial ischemia. N Eng J Med 1995; 333: 1267-72.

  9. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345: 351-8.

  10. Kloner RA, Rezkalla S. Cocaine and the heart. N Engl J Med 2003, 348(6): 487-8.

  11. Souza y MM. Diagnóstico y Tratamiento de los Síndromes Adictivos. México: Ciencia y Cultura Latinoamérica; 2000.

  12. Souza y MM, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI. Craving, adicción etílica y terapéutica. Archivos de Neurociencias México 2000; 5(4): 201-4.

  13. Arif A (ed.). Adverse Health Consequences of Cocaine Abuse. Geneva: World Health Organization; 1987.

  14. Miller NS, Gold MS. Concurrent cocaine withdrawal is associated with reduced severity of alcohol withdrawal. Comprehensive Psychiatry 2003; 36(6): 441-7.

  15. Organización Mundial de la Salud, OMS. Clasificación Internacional de Enfermedades CIE-10. Capítulo V. Trastornos Mentales. Ginebra: Organización Mundial de la Salud; 1993.

  16. Clapp L, Martin B, Beresford TP. Sublingual cocaine: novel recurrence of an ancient practice. Clinical Neuropharmacology 2004; 27(2): 93-4.

  17. Gold MS. The Neurobiology of Addictive Disorders: The Role of Dopamine, Endorphin, and Serotonin. In: Miller SN (ed.).The principles and Practice of Addictions in Psychiatry. W.B. Saunders Company; 1997.

  18. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642-52.

  19. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Behav Pharmacol 2002; 15(8): 284-96.

  20. Goodman & Gillman’s pharmacology. Drugs used for the treatment of miocardial ischemia. 10th Ed. The McGraw-Hill Companies, Inc.; 2006.

  21. Ellinwood EH. Drug Addiction and Its Treatment: Nexus of neuroscience and behavior. N Engl J Med 1997; 337: 1094-5.

  22. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345: 351-8.

  23. Souza y MM, Díaz Barriga SL, Guisa CVM. Adicciones: neuroquímica y terapéutica. Rev Mex Neuroci 2004; 5(6): 619-34.

  24. Souza y MM, Cruz MDL, Díaz Barriga SL, Guisa CVM. Toxicología y manejo de los síndromes de intoxicación y abstinencia por psicotrópicos. Rev Mex Neuroci 2007; 8(2): 170-88.

  25. Kampman KM, Alterman AI, Volpicelli JR, Maany I. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav 2001; 15: 52-9.

  26. Cone EJ, Welch MJ, Babecki MB. Hair Testing for Drugs of Abuse: International Research on Standards and Technology. In: Cone, Welch & Babecki (eds.). NIDA US Department of Health and Human Services, PHS/NIH, Nº 95-98; 1995.

  27. Erwin MB, Deliargyris EN. Cocaine-associated chest pain. Am J Med Sci 2002; 324: 37-44.

  28. Souza y MM. Adicciones. Clínica y Terapéutica. México: Ed. Alfil; 2007.

  29. Kaplan H, Sakock B. Kaplan & Sadock’s Synopsis of Psychiatry. 8th Ed. Baltimore: Williams & Wilkins; 1998.

  30. Kampman KM, Dackis C, Lynch KG, Pettinati H, Tirado C, Gariti P, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug and Alcohol Dependence 2006; 85: 129-37.

  31. Miller WR, Westerberg VS, Harris RJ, Tonigan JS. What predicts relapse? Prospective testing of antecedent models. Addiction 1996; 91: S155-72.

  32. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocainedependence treatment seekers with adult ADHD: a doubleblind comparison of methylphenidate and placebo. Drug and Alcohol Dependence 2007; 87: 20-9.

  33. Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR. Buphrenophine: dose related effects on cocaine and opioid use on cocaine-abusing opiod-dependent humans. Biol Psychiatry 1993; 34: 66-74.

  34. Kinnell HG. Bupropion for smokers: drug is almost identical in structure to diethylpropion, a controlled drug. Br Med J 2001; 322: 431-2.

  35. Prado GA, Martínez AJ, Martínez MJ, Mercado CG, Souza y MM. Bupropion y uso de cocaína. Rev Mex Neuroci 2000; 1(3): 39-41.

  36. Stahl SM (ed.). Essential Psychopharmacology. Neuroscientific Basis and Practical Applications. 2nd Ed. Cambridge University Press; 2005.

  37. Souza y MM. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 57-69.

  38. American Psychiatric Association, APA. Diagnostic and Statistical Manual of mental Disorders. 4a Ed. Washington: American Psychiatric American Psychiatric Association; 2000.

  39. Souza y MM. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Rev Mex Neuroci 2003; 4(5): 326-30.

  40. Levin FR, Bisaga A, Kleber HD. Los tratamientos farmacológicos para el abuso de sustancias: presentes y prometedores. Psiquiatría y Salud Integral 2002; 35-45.

  41. Souza y MM, Quijano BEM, Díaz Barriga SL, Guisa CVM, Lorenzo AS, Gaucin RR. Historia clínica psiquiátrica codificada para adicciones. Hcpca. Psiquiatría 1998; 14(1): 9-25.

  42. Farre M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, Cami J. Alcohol and cocaine interaction in humans. J Pharmacol Experiment Therap 1993; 266(3): 1364-73.

  43. Souza y MM. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuro 2001; 2(1): 25-7.

  44. Kosten TR, Rossen M, Bond J, Settkes M, St. Calir Roberts J, Shields J, Jack L. Human Therapeutic cocaine vaccine: safety and immunegenecity. Vaccine 2002; 20: 1196-1204.

  45. Oficina de las Naciones Unidas Contra la Droga y el Delito. PNUFID. Tratamiento contemporáneo del abuso de drogas: análisis de las pruebas científicas. N.Y.: ONU; 2003.

  46. NIDA. The National Institute on Drug Abuse. Understanding Drug Abuse and Addiction: What Science Says. U.S. Department of Health and Human Services; 2002.

  47. NIDA. The National Institute on Drug Abuse. Information for Researchers and Health Professionals. U.S. Department of Health and Human Services; 2003.

  48. Camí J, Farré M. Mechanisms of Disease: Drug Addiction. N Engl J Med 2003; 349: 975-86.

  49. Souza y MM. Adicciones, Nosología y terapéutica. Revista Electrónica de Medicina Neuropsicológica 2008; 9: 96.

  50. Diario Oficial. Norma Oficial Mexicana NOM 028-SSA2-1999 para la Prevención, Tratamiento y Control de las Adicciones. Viernes 18 de agosto de 2000.

  51. Diario Oficial. Norma Oficial Mexicana NOM-025-SSA2-1994, para la Prestación de Servicios de Salud en Unidades de Atención Integral Hospitalaria Médico-Psiquiátrica. Miércoles 15 de noviembre de 1995.

  52. Diario Oficial. Proyecto de Norma Oficial Mexicana NOM-168-SSA1- 1998, del Expediente Clínico. Lunes 7 de diciembre de 1998.

  53. Llosa T, Chang-Fung JE. Handbook on Oral Cocaine in Addictions. 2nd Ed. Proceedings on NIDA/CPDD 69th Annual Scientific Meeting, Quebec City, Canada, June 16-21; 2007.

  54. Grabowski J, Shearer J, Meerrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004; 29(7): 1439-64.

  55. Vocci F, Elkashef A. Pharmacotherapy and other treatment for cocaine abuse and dependence. Curr Opin Psychiatry 2005; 18: 265-70.

  56. World Health Organization. Consultation on WHO Drug Substitution Project, Report, WHO/PSA/96.3, Geneva, May, Report. 1995.

  57. Souza y MM. Por una psiquiatría de las adicciones. Rev Mex Neuroci 2003; 4(4): 206-8.




2020     |     www.medigraphic.com